https://doi.org/10.1016/j.eururo.2023.05.021
A
Andrea Loehr
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
125
Papers
2.4K
Citations
17
h-index
21
i10-index
Andrea Loehr is an academic researcher. The author has contributed to research in topics: Prostate Cancer Treatment and Research & PARP inhibition in cancer therapy & Cancer Genomics and Diagnostics. The author has an h-index of 17, co-authored 107 publications.
Papers by this author
worksRucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
2023 · European Urology · 84 citations
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
2018 · Leukemia · 62 citations
https://doi.org/10.1038/s41375-018-0017-0
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation
2021 · European Journal of Cancer · 44 citations
https://doi.org/10.1016/j.ejca.2021.09.028
A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
2005 · British Journal of Cancer · 7 citations
https://doi.org/10.1038/sj.bjc.6602886
Supplementary Data 1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27938310
AI Evaluation Practices Consensus
2025 · Open Science Framework · 0 citations
https://doi.org/10.17605/osf.io/m7hpt
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat